Trial Profile

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REGV131 LNP1265 (Primary)
Indications Haemophilia B
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms BEYOND-9
Sponsors Regeneron Pharmaceuticals

Most Recent Events

26 Nov 2024 Planned End Date changed from 15 Aug 2032 to 17 Dec 2032.
26 Nov 2024 Planned primary completion date changed from 15 Aug 2032 to 17 Dec 2032.
19 Sep 2024 Planned End Date changed from 3 Jul 2032 to 15 Aug 2032.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com